Biogen Investor Relations Material
Latest events
Q2 2024
Latest reports from Biogen Inc
Developing Breakthrough Medications
Biogen is a multinational biotechnology company operating in the field of discovery, development, and sale of various. The company was established in 1978 and is based in Cambridge, Massachusetts. Over the years, Biogen has emerged as a key player in the biotech sector, specifically in neurology, with several therapies targeting multiple sclerosis (MS) and spinal muscular atrophy (SMA). Beyond neurology, their portfolio spans therapies for conditions such as hemophilia and other rare disorders.
Decades of Experience
Founded in 1978, Biogen stands as one of the world's oldest independent biotechnology companies. Its roots trace back to a group of scientists who recognized the potential of biotechnology to produce breakthrough medicines. In addition to its offerings of medications currently on the market, the company has consistently invested in research and development, leading to numerous innovations in the biotechnology sector. Biogen has consistently been able to develop marketable medications that make a positive impact on patient health. The company has expanded through a combination of organic growth as well as through collaborations and acquisitions over the years.
The Portfolio
Biogen has a vast therapeutic portfolio of various medications. The company has developed a range of therapies over the years, with several being first-of-their-kind or best-in-class. A standout is their focus on neurology, particularly in multiple sclerosis. Products like TECFIDERA and AVONEX have been game-changers in the MS treatment landscape. Additionally, SPINRAZA, designed for spinal muscular atrophy, is another prime example of Biogen's novel treatments addressing severe medical conditions. The company is also constantly working on developing new drugs
A Global Company
The company has a significant global presence, spanning countries across multiple continents. Their expansive distribution network ensures that their therapies are accessible to patients around the world. This is nothing unique for this type of company and the world's largest biotechnology companies and medication producers such as Pfizer, Eli Lilly, and Amgen, to mention a few, all operate on a global scale.